{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:53:10Z","timestamp":1787964790012,"version":"build-2784847793"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T00:00:00Z","timestamp":1493942400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s12032-017-0972-8","type":"journal-article","created":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T09:04:15Z","timestamp":1493975055000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Antiangiogenics and immunotherapies in cervical cancer: an update and future\u2019s view"],"prefix":"10.1007","volume":"34","author":[{"given":"Daniela","family":"Luvero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Plotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Scaletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Capriglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Montera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianina","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ciuffreda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Carassiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Oliveti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Angioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,5]]},"reference":[{"issue":"1","key":"972_CR1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ajog.2015.07.022","volume":"214","author":"KS Pfaendler","year":"2016","unstructured":"Pfaendler KS, Tewari KS. Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol. 2016;214(1):22\u201330.","journal-title":"Am J Obstet Gynecol"},{"issue":"2015","key":"972_CR2","first-page":"E359","volume":"136","author":"J Ferlay","year":"2012","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN. Int J Cancer. 2012;136(2015):E359\u201386.","journal-title":"Int J Cancer"},{"issue":"15","key":"972_CR3","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJM199904153401503","volume":"340","author":"HM Keys","year":"1999","unstructured":"Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340(15):1154\u201361.","journal-title":"N Engl J Med"},{"issue":"15","key":"972_CR4","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1056\/NEJM199904153401501","volume":"340","author":"M Morris","year":"1999","unstructured":"Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340(15):1137\u201343.","journal-title":"N Engl J Med"},{"key":"972_CR5","unstructured":"Peters WA, Liu PY, Barrett RGW. Cisplatin, 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive therapy in high risk, early stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: report of a phase III inter group study. Presented at Soc Gynecol Oncol 30th annual meeting, San Francisco, CA, 5\u20139 Feb, 1999; 1999."},{"issue":"15","key":"972_CR6","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJM199904153401502","volume":"340","author":"PG Rose","year":"1999","unstructured":"Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144\u201353.","journal-title":"N Engl J Med"},{"issue":"5","key":"972_CR7","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1200\/JCO.1999.17.5.1339","volume":"17","author":"CW Whitney","year":"1999","unstructured":"Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17(5):1339\u201348.","journal-title":"J Clin Oncol"},{"key":"972_CR8","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1111\/IGC.0b013e3181f967ed","volume":"20","author":"N Colombo","year":"2010","unstructured":"Colombo N. Critical review of neoadjuvant chemotherapy followed by surgery for locally advanced cervical cancer. Int J Gynecol Cancer. 2010;20:S47\u20138.","journal-title":"Int J Gynecol Cancer"},{"key":"972_CR9","doi-asserted-by":"crossref","unstructured":"Dishe S. Radiotherapy of cervical cancer. Clim Obstet. Gynecol. 12, 203\u2014227. 17 (1985).","DOI":"10.1016\/S0306-3356(21)00103-5"},{"key":"972_CR10","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/0090-8258(89)90627-6","volume":"32","author":"JF Barter","year":"1989","unstructured":"Barter JF, Soong SJ, Shingleton HM, Hatch KD. Orr JW\u2019 Jr. Complications Of combined radical hysterectomy-postoperative radiation therapy in women with early stage cervical cancer. Gynecologic Oncol. 1989;32:292\u20136.","journal-title":"Gynecologic Oncol"},{"issue":"11 Suppl 2","key":"972_CR11","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1111\/IGC.0b013e3181f967ed","volume":"20","author":"N Colombo","year":"2010","unstructured":"Colombo N, Peiretti M. Critical review of neoadjuvant chemotherapy followed by surgery for locally advanced cervical cancer. Int J Gynecol Cancer. 2010;20(11 Suppl 2):S47\u20138.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"972_CR12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1200\/JCO.2002.20.1.179","volume":"20","author":"P Benedetti-Panici","year":"2002","unstructured":"Benedetti-Panici P, Greggi S, Colombo A, Amoroso M, Smaniotto D, Giannarelli D, Amunni G, Raspagliesi F, Zola P, Mangioni C, Landoni F. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol. 2002;20(1):179\u201388.","journal-title":"J Clin Oncol"},{"key":"972_CR13","doi-asserted-by":"publisher","unstructured":"Rydzewska L, Tierney J, Vale CL, Symonds PR. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev. 2012. doi: 10.1002\/14651858.CD007406.pub3 .","DOI":"10.1002\/14651858.CD007406.pub3"},{"key":"972_CR14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1525-1438.1998.09862.x","volume":"8","author":"J Sardi","year":"1998","unstructured":"Sardi J, Sananes C. Neoadjuvant chemotherapy in cervical carcinoma stage IIB: a randomized controlled trial. Int J Gynecol Cancer. 1998;8:441\u201350.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"972_CR15","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ygyno.2008.05.026","volume":"110","author":"H Chen","year":"2008","unstructured":"Chen H, Liang C, Zhang L, Huang S, Wu X. Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study. Gynecol Oncol. 2008;110(3):308\u201315.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"972_CR16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3802\/jgo.2009.20.1.22","volume":"20","author":"YH Cho","year":"2009","unstructured":"Cho YH, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Comparative study of neoadjuvant chemotherapy before radical hysterectomy and radical surgery alone in stage IB2-IIA bulky cervical cancer. J Gynecol Oncol. 2009;20(1):22\u20137.","journal-title":"J Gynecol Oncol"},{"issue":"2","key":"972_CR17","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ygyno.2007.04.007","volume":"106","author":"GL Eddy","year":"2007","unstructured":"Eddy GL, Bundy BN, Creasman WT, Spirtos NM, Mannel RS, Hannigan E, O\u2019Connor D. Treatment of (\u201cbulky\u201d) stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic\/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol Oncol. 2007;106(2):362\u20139 Epub 2007 May 9.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"972_CR18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1447-0756.2006.00404.x","volume":"32","author":"HB Cai","year":"2006","unstructured":"Cai HB, Chen HZ, Yin HH. Randomized study of preoperative chemotherapy versus primary surgery for stage IB cervical cancer. J Obstet Gynaecol Res. 2006;32(3):315\u201323.","journal-title":"J Obstet Gynaecol Res"},{"issue":"8","key":"972_CR19","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/JCO.2000.18.8.1740","volume":"18","author":"TC Chang","year":"2000","unstructured":"Chang TC, Lai CH, Hong JH, Hsueh S, Huang KG, Chou HH, Tseng CJ, Tsai CS, Chang JT, Lin CT, Chang HH, Chao PJ, Ng KK, Tang SG, Soong YK. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. J Clin Oncol. 2000;18(8):1740\u20137.","journal-title":"J Clin Oncol"},{"key":"972_CR20","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1200\/JCO.2008.16.4368","volume":"26","author":"JF Vale Tierney","year":"2008","unstructured":"Vale Tierney JF, Stewart LA, et al. Chemoradiotherapy for cervical cancer meta-analysis collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J. Clin. Oncol. 2008;26:5802\u201312.","journal-title":"J. Clin. Oncol"},{"issue":"2","key":"972_CR21","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ygyno.2012.07.104","volume":"127","author":"R Angioli","year":"2012","unstructured":"Angioli R, Plotti F, Montera R, Aloisi A, Luvero D, Capriglione S, Terranova C, De Cicco Nardone C, Muzii L, Benedetti-Panici P. Neoadjuvant chemotherapy plus radical surgery followed by chemotherapy in locally advanced cervical cancer. Gynecol Oncol. 2012;127(2):290\u20136.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"972_CR22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1586\/14737140.2014.866520","volume":"14","author":"R Angioli","year":"2014","unstructured":"Angioli R, Luvero D, Aloisi A, Capriglione S, Gennari P, Linciano F, Li Destri M, Scaletta G, Montera R, Plotti F. Adjuvant chemotherapy after primary treatments for cervical cancer: a critical point of view and review of the literature. Expert Rev Anticancer Ther. 2014;14(4):431\u20139.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"972_CR23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ygyno.2015.09.082","volume":"139","author":"R Angioli","year":"2015","unstructured":"Angioli R, Plotti F, Aloisi A, Scaletta G, Capriglione S, Luvero D, Fiore L, Terranova C, Montera R, Panici PB. A randomized controlled trial comparing four versus six courses of adjuvant platinum-based chemotherapy in locally advanced cervical cancer patients previously treated with neo-adjuvant chemotherapy plus radical surgery. Gynecol Oncol. 2015;139(3):433\u20138.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"972_CR24","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1517\/14656566.2015.1010511","volume":"16","author":"LS Krill","year":"2015","unstructured":"Krill LS, Tewari KS. Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer. Expert Opin Pharmacother. 2015;16(5):675\u201383.","journal-title":"Expert Opin Pharmacother"},{"issue":"19","key":"972_CR25","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","volume":"358","author":"RS Kerbel","year":"2008","unstructured":"Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19):2039\u201349.","journal-title":"N Engl J Med"},{"key":"972_CR26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0046-8177(95)90119-1","volume":"26","author":"LF Brown","year":"1995","unstructured":"Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol. 1995;26:86\u201391.","journal-title":"Hum Pathol"},{"key":"972_CR27","first-page":"4727","volume":"53","author":"LF Brown","year":"1993","unstructured":"Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 1993;53:4727\u201335.","journal-title":"Cancer Res"},{"key":"972_CR28","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/(SICI)1097-0142(19960801)78:3<454::AID-CNCR12>3.0.CO;2-Y","volume":"7","author":"AJ Guidi","year":"1996","unstructured":"Guidi AJ, Abu-Jawdeh G, Tognazzi K, Dvorak HF, Brown LF. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer. 1996;7:454\u201360.","journal-title":"Cancer"},{"key":"972_CR29","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ygyno.2014.03.574","volume":"133","author":"P Wimberger","year":"2014","unstructured":"Wimberger P, Chebouti I, Kasimir-Bauer S, et al. Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance. Gynecol Oncol. 2014;133:467\u201372.","journal-title":"Gynecol Oncol"},{"key":"972_CR30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ygyno.2006.03.023","volume":"103","author":"JD Wright","year":"2006","unstructured":"Wright JD, Viviano D, Powell MA, et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol. 2006;103:489\u201393.","journal-title":"Gynecol Oncol"},{"key":"972_CR31","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1200\/JCO.2008.18.9043","volume":"27","author":"BJ Monk","year":"2009","unstructured":"Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:1069\u201374.","journal-title":"J Clin Oncol"},{"issue":"1179\u201384","key":"972_CR32","first-page":"28","volume":"83","author":"TE Schefter","year":"2012","unstructured":"Schefter TE, Winter K, Kwon JS, et al. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417. Int J Radiat Oncol Biol Phys. 2012;83(1179\u201384):28.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"972_CR33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijrobp.2013.10.022","volume":"88","author":"T Schefter","year":"2014","unstructured":"Schefter T, Winter K, Kwon JS, et al. RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. Int J Radiat Oncol Biol Phys. 2014;88:101\u20135.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"972_CR34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ygyno.2013.04.009","volume":"130","author":"I Zighelboim","year":"2013","unstructured":"Zighelboim I, Wright JD, Gao F, et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol. 2013;130:64\u20138.","journal-title":"Gynecol Oncol"},{"key":"972_CR35","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","volume":"370","author":"KS Tewari","year":"2014","unstructured":"Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370:734\u201343.","journal-title":"N Engl J Med"},{"key":"972_CR36","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ygyno.2009.08.012","volume":"116","author":"HJ Mackay","year":"2010","unstructured":"Mackay HJ, Tinker A, Winquist E, et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol. 2010;116:163\u20137.","journal-title":"Gynecol Oncol"},{"key":"972_CR37","unstructured":"European Medicines Agency (2013). Avastin: summary of product characteristics. http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_Product_Information\/human\/000582\/ ."},{"issue":"5","key":"972_CR38","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","volume":"349","author":"JC Yang","year":"2003","unstructured":"Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427\u201334.","journal-title":"N Engl J Med"},{"key":"972_CR39","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391\u2013400.","journal-title":"Nat Rev Drug Discov"},{"issue":"23","key":"972_CR40","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335\u201342.","journal-title":"N Engl J Med"},{"issue":"3","key":"972_CR41","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1470-2045(15)70004-5","volume":"16","author":"RT Penson","year":"2015","unstructured":"Penson RT, Huang HQ, Wenzel LB, Monk BJ, Stockman S, Long HJ 3rd, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Method M, Michael H, Tewari KS. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol. 2015;16(3):301\u201311.","journal-title":"Lancet Oncol"},{"key":"972_CR42","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2009.26.9571","volume":"28","author":"BJ Monk","year":"2010","unstructured":"Monk BJ, Mas Lopez L, Zarba JJ, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2010;28:3562\u20139.","journal-title":"J Clin Oncol"},{"key":"972_CR43","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1200\/JCO.2011.38.8777","volume":"29","author":"BJ Monk","year":"2011","unstructured":"Monk BJ, Pandite LN. Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2011;29:4845.","journal-title":"J Clin Oncol"},{"issue":"15","key":"972_CR44","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S1470-2045(15)00220-X","volume":"16","author":"RP Symonds","year":"2015","unstructured":"Symonds RP, Gourley C, Davidson S, et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervix cancer (CIRCCa): A randomised, double blind, placebo-controlled phase 2 trial. Lancet Oncol. 2015;16(15):1515\u201324.","journal-title":"Lancet Oncol"},{"issue":"1","key":"972_CR45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijrobp.2015.09.009","volume":"94","author":"MF Milosevic","year":"2016","unstructured":"Milosevic MF, Townsley CA, Chaudary N, Clarke B, Pintilie M, Fan S, Glicksman R, Haider M, Kim S, MacKay H, Yeung I, Hill RP, Fyles A, Oza AM. Sorafenib increases tumor hypoxia in cervical cancer patients treated with radiation therapy: results of a Phase 1 clinical study. Int J Radiat Oncol Biol Phys. 2016;94(1):111\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"972_CR46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2010.02.012","volume":"77","author":"FA Schutz","year":"2011","unstructured":"Schutz FA, Choueiri TK, Sternberg CN. Pazopanib. Clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol. 2011;77:163\u201371.","journal-title":"Crit Rev Oncol Hematol"},{"key":"972_CR47","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s12094-014-1219-1","volume":"16","author":"J Bellmunt","year":"2014","unstructured":"Bellmunt J, Puente J, Garcia de Muro J, Lainez N, Rodr\u00edguez C, Duran I. SEOM clinical guidelines for the treatment of renal cell carcinoma. Clin Transl Oncol. 2014;16:1043\u201350.","journal-title":"Clin Transl Oncol"},{"key":"972_CR48","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clinthera.2014.11.010","volume":"37","author":"RN Eskander","year":"2015","unstructured":"Eskander RN, Tewari KS. Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer. Clin Ther. 2015;37:20\u201338.","journal-title":"Clin Ther"},{"key":"972_CR49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1189\/jlb.1212631","volume":"94","author":"MK Callahan","year":"2013","unstructured":"Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol. 2013;94:41\u201353.","journal-title":"J Leukoc Biol"},{"key":"972_CR50","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323.","journal-title":"N Engl J Med"},{"key":"972_CR51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1756-9966-33-29","volume":"33","author":"P Vici","year":"2014","unstructured":"Vici P, Mariani L, Pizzuti L, Sergi D, Di Lauro L, Vizza E, et al. Immunologic treatments for precancerous lesions and uterine cervical cancer. J Exp Clin Cancer Res. 2014;33:29.","journal-title":"J Exp Clin Cancer Res"},{"key":"972_CR52","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1158\/0008-5472.CAN-12-2384","volume":"73","author":"S Lyford-Pike","year":"2013","unstructured":"Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, et al. Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73:1733\u201341.","journal-title":"Cancer Res"},{"key":"972_CR53","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"C Robert","year":"2014","unstructured":"Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109\u201317.","journal-title":"Lancet"},{"key":"972_CR54","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1158\/1078-0432.CCR-14-1099","volume":"20","author":"KS Tewari","year":"2014","unstructured":"Tewari KS, Monk BJ. New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy. Clin Cancer Res. 2014;20:5349\u201358.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"972_CR55","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","volume":"372","author":"EA Joura","year":"2015","unstructured":"Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Chan IS, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A, Broad Spectrum HPV. Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711\u201323.","journal-title":"N Engl J Med"},{"key":"972_CR56","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.critrevonc.2016.03.020","volume":"102","author":"R Angioli","year":"2016","unstructured":"Angioli R, Lopez S, Aloisi A, Terranova C, De Cicco C, Scaletta G, Capriglione S, Miranda A, Luvero D, Ricciardi R, Montera R, Plotti F. Ten years of HPV vaccines: state of art and controversies. Crit Rev Oncol Hematol. 2016;102:65\u201372.","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-017-0972-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-017-0972-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-017-0972-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T12:25:13Z","timestamp":1692793513000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-017-0972-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,5]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["972"],"URL":"https:\/\/doi.org\/10.1007\/s12032-017-0972-8","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,5]]},"article-number":"115"}}